The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
Data from the clinical trial showed Zepbound helped obese and overweight adults in the trial lose more weight and lose it faster than adults taking Ozempic or Wegovy. Semaglutide (Rybelsus): An ...